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Background: Longitudinal analyses of comorbid conditions in women with breast cancer are few.
Methods: Using Surveillance, Epidemiology, and End Results–Medicare data, we included 51950 women aged ≥66
years with in situ and stage I to IV breast cancer diagnosed in 1998–2002. We identiﬁed the prevalence and incidence
of 34 comorbid conditions in these women, as well as in a matched cohort without cancer whose rates were
standardized to the age and race/ethnicity distribution of the cancer patients. We also estimated rates of ofﬁce
encounters and diagnostic or testing procedures during the 12 months before diagnosis.
Results: The prevalence of most conditions at diagnosis was comparable among breast cancer and noncancer
patients. New conditions after diagnosis were more common in breast cancer patients, and the incidence rates
increased with higher stage at diagnosis. Before diagnosis, women presenting with stage IV disease had 41% [95%
conﬁdence interval (CI) 38% to 43%] fewer physician encounters and 34% (95% CI 24% to 31%) fewer unique
diagnostic tests than women diagnosed with carcinoma in situ.
Conclusions: Many comorbid conditions are identiﬁed as a consequence of the breast cancer diagnosis. There
appears to be an important contribution from a lack of interaction with the health care system before diagnosis.
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introduction
Breast cancer is a common disease in women, and its incidence
increases with age [1, 2]. Understanding the interplay between
breast cancer and comorbid conditions is important because
comorbidities inﬂuence decisions about the appropriate course
of treatment and are independent risk factors for survival [3–
5]. In addition, comorbidities may limit patients’ eligibility for
clinical trials, and consequently, the generalizability of study
results to the overall population [6]. For these reasons,
comorbidity burden is a key component of the diagnosis and
treatment process as well as postcancer care.
If higher stage at diagnosis were related to greater
comorbidity burden, as might be hypothesized, it would
suggest that comorbidity considerations become more
complicated for women with more advanced-stage breast
cancer. Although there is no direct evidence of a signiﬁcant
reservoir of undiagnosed comorbid conditions that increases
with stage, there are studies showing that more screening
procedures and more ambulatory care visits are each associated
with earlier stage at diagnosis [7, 8]. Based on this, it would be
reasonable to surmise that those patients who do not seek care
for signs and symptoms of cancer, or who delay screening,
may ignore other health issues as well [9]. Such undiagnosed
conditions would be expected to be picked up in the extensive
testing and related evaluations conducted after cancer
diagnosis. In the clinical trial setting, any conditions not
identiﬁed at diagnosis could complicate the analysis and
interpretation of the trial data. However, despite its relevance
to patient care, the incidence of new comorbid conditions after
cancer diagnosis has not, to our knowledge, been compared
across stages, or to a control population of individuals without
cancer.
Therefore, the purpose of this study was threefold: to
quantify the comorbidity burden at the time of diagnosis by
comparing the prevalence of a variety of conditions in women
with and without breast cancer; to estimate the previously
undetected comorbidity burden elicited after cancer diagnosis
by estimating incidence rates for a variety of conditions in
these women; and to explore whether the identiﬁcation of
comorbid conditions in breast cancer patients is related to the
degree of precancer interaction with the health system in these
women.
methods
data source
This study used the Surveillance, Epidemiology, and End Results
(SEER)–Medicare database, which links SEER cancer registry data with
Medicare data. Medicare-eligible persons are primarily individuals aged
≥65 in the United States, although other younger populations are
included based on disability or speciﬁc medical conditions [10–12]. Our
dataset also included a separately created 5% random sample of
noncancer patients from the Medicare program in the same catchment
areas as those used in the SEER program for use as a reference (i.e.
control) population.
study population and observation period
Patients were diagnosed with in situ and stage I to IV breast cancer
between 1 January 1998 and 31 December 2002 and had Medicare claims
available from 1997 through 2005. Women with previous primary cancer
diagnoses in the SEER registry were excluded as were women who died in
the month of diagnosis. Follow-up was based on data for covered health
care services, including hospital, physician, and outpatient claims. Cancer
and noncancer subjects were at least 66 years old to allow at least 12
months of Medicare claims data for identifying prevalent conditions before
diagnosis. All patients were required to have both Part A and B Medicare
coverage (i.e. fee-for-service) during the observation period, and all patients
in managed care plans were excluded because detailed medical claims are
not available for these individuals. Follow-up ended at the earliest of the
following events: end of the observation period, end of Part A and B
coverage, or death.
An identically sized cohort of women without cancer (i.e. noncancer
patients) was created by matching on both time of diagnosis and
geographic area to the cohort of women with cancer (other variables were
controlled using stratiﬁcation and adjustment as discussed below). For time
matching, the SEER month and year of cancer diagnosis for each cancer
patient were used to identify potential noncancer matches who had
appropriate Medicare coverage on the same date. The ﬁrst day of this
month was assigned as the diagnosis index date for both the breast cancer
patient and her randomly selected noncancer control. For geographic area
matching, the county of residence was used ﬁrst and the state of residence
was used if no county match was available. Subjects in the noncancer
cohort were known to be cancer-free through 2002.
patient characteristics
For women with breast cancer, the SEER data were the source for
identifying the date of cancer diagnosis, cancer site, and tumor
characteristics. Stage at breast cancer diagnosis was based on the SEER–
Modiﬁed American Joint Committee on Cancer (AJCC) stage variable [13].
Hormone receptor status included estrogen receptor (ER) and progesterone
receptor status (PR). For all patients, age was given in years at the diagnosis
index date. Race/ethnicity was based on the following categories: white,
black, Hispanic, or other (predominately American Indian, Native Alaskan,
Paciﬁc Islander, and Asian).
The algorithm from the National Cancer Institute (NCI) for
constructing a comorbidity index was also used for all patients to estimate
a modiﬁed Charlson Comorbidity Index incorporating the adaptations
suggested by Deyo and Romano (excluding cancer as a condition) [14–16].
Scores were categorized into 0, 1, and ≥2.
deﬁnitions of comorbid conditions
Medicare claims data were used for identifying prevalent and incident
conditions of interest throughout the observation period. Supplemental
Appendix Table S1 (available at Annals of Oncology online) provides
the International Classiﬁcation of Diseases, ninth edition (ICD-9) codes
used to identify the 34 conditions in both breast cancer and noncancer
women [17]. These conditions were chosen to represent common
comorbid conditions in older adults, as well as common consequences
of chemotherapy (referred to as ‘adverse events’). Diagnoses recorded
on claims for inpatient stays were counted at the time of their ﬁrst
occurrence. Diagnoses in outpatient facility and physician claims were
assessed similarly to the NCI comorbidity algorithm, which requires two
diagnoses at least 30 days apart to identify a comorbidity (taking the
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conditions classiﬁed as adverse events, only claims associated with an
inpatient or emergency department visit were counted, and, because
‘rule-out’ claims are less of a problem in the hospital setting, only a
single diagnosis code was required. In this way, they align with the
concept of ‘serious adverse events’ often used in clinical trials, although
they may represent chronic conditions and/or be unrelated to cancer-
directed therapy.
counts of physician encounters and diagnostic
tests
As a simple approach to measuring interactions with the health system, we
counted the number of physician encounters and the number of unique
diagnostic tests carried out in the breast cancer and noncancer patient
cohorts during the 12 months before, and after, the diagnosis index date.
Physician encounters were deﬁned as physician ofﬁce visits using
Healthcare Common Procedure Coding System (HCPCS) codes [18].
Table 1. Demographic characteristics of the breast cancer and noncancer patient cohorts
Characteristic Breast cancer patients Noncancer patients
N (%) N (%)
Age (years)
a 66–69 9690 (18.8) 9913 (19.2)
70–74 13469 (26.1) 12451 (24.1)
75–79 13039 (25.3) 11721 (22.7)
≥ 80 15392 (29.8) 17505 (33.9)
Race/ethnicity White 44712 (86.7) 43671 (84.7)
Black 3345 (6.5) 3781 (7.3)
Asian/Other 1843 (3.6) 2999 (5.8)
Hispanic 1690 (3.3) 1139 (2.2)
SEER region Georgia (Atlanta/Rural Georgia) 2027 (3.9) 2027 (3.9)
California
b 15558 (30.2) 15558 (30.2)
Connecticut 4225 (8.2) 4225 (8.2)
Hawaii 876 (1.7) 876 (1.7)
Iowa 4544 (8.8) 4544 (8.8)
Kentucky 3239 (6.3) 3239 (6.3)
Louisiana 2731 (5.3) 2731 (5.3)
Michigan (Detroit) 5013 (9.7) 5013 (9.7)
New Jersey 6726 (13) 6726 (13)
New Mexico 1408 (2.7) 1408 (2.7)
Utah 1664 (3.2) 1664 (3.2)
Washington (Seattle/Puget Sound) 3579 (6.9) 3579 (6.9)
NCI comorbidity score
c 0 34296 (68.6) 30721 (63.3)
1 10844 (21.7) 10797 (22.2)
≥2 4833 (9.7) 7033 (14.5)
Stage at diagnosis
d In situ 7532 (14.6) N/A
I 22235 (43.1)
II 14753 (28.6)
III 2558 (5)
IV 2191 (4.3)
Unknown 2282 (4.4)
Tumor grade at diagnosis Well differentiated 9861 (19.1) N/A
Moderately differentiated 19057 (26.9)
Poorly differentiated 12564 (24.4)
Undifferentiated 1426 (2.8)
Other and unknown 8682 (16.8)
ER/PR status Positive 30613 (59.3) N/A
Negative 5112 (9.9)
Unknown 15865 (30.8)
Year of diagnosis 1998 6412 (12.4) N/A
1999 6429 (12.5)
2000 12915 (25)
2001 13085 (25.4)
2002 12749 (24.7)
aAge at diagnosis index date.
bCalifornia includes Los Angeles, San Francisco/Oakland, San Jose/Monterey, and Greater California.
cComorbidity index based on conditions identiﬁed in the 12 months before the diagnosis index date.
dStage based on the American Joint Committee on Cancer’s staging system (third edition).
ER, estrogen receptor; NCI, National Cancer Institute; PR, progesterone receptor; SEER, Surveillance, Epidemiology, and End Results.
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following: radiology, pathology and laboratory, psychiatric diagnostics,
gastroenterology diagnostics, echocardiography, intracardiac
electrophysiology, cerebrovascular arterial studies, pulmonary testing,
glucose monitoring, electroencephalography, and central nervous system
assessments (see supplemental Appendix Table S2, available at Annals of
Oncology online). One physician encounter per day per patient was
counted, and one of each type of diagnostic test (HCPCS code) per patient
was counted.
statistical analyses
For each condition, standardized rates were estimated for each of the three
observation periods (before, 3 months after, and 12 months after the index
date). These rates were estimated overall as well as within age, race/
ethnicity, and stage-speciﬁc (for cancer patients) strata (data not shown).
The cancer rates for each stratum were standardized to the age, race/
ethnicity, and stage-speciﬁc characteristics of the total breast cancer cohort
[19]. Rates in the noncancer patients were standardized to the age and
race/ethnicity distribution of the total breast cancer cohort to facilitate
comparisons.
Prevalence was deﬁned as the proportion of study subjects with a
particular condition as of the index date using claims before the diagnosis
index date. Binomial conﬁdence intervals (CIs) were calculated for each
prevalence proportion. Incidence rates were deﬁned as new diagnoses after
the index date in patients free of the condition at diagnosis. If the
comorbid condition was not diagnosed, subjects were censored at death,
the end of coverage according to the eligibility criteria, or the end of the
observation period. Incidence rates per 1000 person-years were estimated.
The 12-month and 3-month rates reﬂect overlapping time periods.
Zero-inﬂated negative binomial models were used to estimate the
average number of visits or tests during the year before the index date by
cancer stage at diagnosis in the breast cancer cohort and to compare the
number of visits or tests between cancer and noncancer patients. These
models were adjusted for age and race/ethnicity [20, 21].
All analyses were conducted in SAS (version 9.2; SAS Institute Inc.,
Cary, NC) and Stata (version 10; Stata Corporation, College Station, TX).
results
There were 51950 women identiﬁed in both the breast cancer
and the noncancer populations. See Table 1 for details on the
cohorts.
The standardized prevalence rates for 27 of the 34
conditions were lower in women with cancer compared with
women without cancer (Table 2). Certain comorbidities were
exceptions to this pattern: atrial ﬁbrillation, hypertension,
diabetes, liver disease, osteoarthritis, thromboembolic events,
and chronic obstructive pulmonary disease. In terms of
incidence rates for all conditions, standardized 3-month and
12-month rates were, with the exception of the 12-month
cardiac arrest rate, always higher in the women with breast
cancer. See Table 3 for incidence rates.
When stratiﬁed by stage at breast cancer diagnosis, for many
comorbid conditions, the prevalence rates were quite variable
(Figure 1 and supplemental Appendix Table S3, available at
Annals of Oncology online). In contrast, the incidence rates for
most conditions increased with higher stage at breast cancer
diagnosis (Figure 2 and supplemental Appendix Table S4,
available at Annals of Oncology online).
Women with and without breast cancer had comparable
numbers of physician encounters in the window of time
beginning 12 months before the cancer diagnosis date and
Table 2. Prevalence proportions for Comorbid conditions in breast cancer
patients and noncancer control patients
Comorbid condition Breast cancer
patients, %
(95% CI)
Noncancer
patients, %
(95% CI)
Adverse events
Anemia 6.09 (5.89–6.3) 7.59 (7.36–7.81)
Diarrhea 1.62 (1.51–1.73) 1.83 (1.71–1.94)
Electrolyte disorder 9.39 (9.15–9.64) 11.34 (11.07–11.61)
Infectious disease 11.95 (11.68–12.23) 14.39 (14.09–14.69)
Infusion reaction 0.43 (0.38–0.49) 0.46 (0.4–0.52)
Neutropenia 0.13 (0.1–0.16) 0.16 (0.13–0.2)
Oral mucositis 0.03 (0.01–0.04) 0.03 (0.01–0.04)
Skin rash (medication
related)
0.13 (0.1–0.16) 0.21 (0.17–0.25)
Skin rash (other) 2.02 (1.9–2.14) 2.36 (2.23–2.49)
Thrombocytopenia 0.55 (0.49–0.62) 0.68 (0.6–0.75)
Cardiac/vascular
Arrhythmia 7.24 (7.01–7.46) 7.41 (7.18–7.63)
Arterial thrombosis 0.29 (0.25–0.34) 0.47 (0.41–0.53)
Atrial ﬁbrillation 9.19 (8.94–9.43) 8.61 (8.37–8.85)
Coronary artery disease 18.35 (18.02–18.68) 19.13 (18.8–19.47)
Congestive heart failure 10.69 (10.43–10.96) 11.6 (11.33–11.86)
Cerebrovascular disease 8.11 (7.88–8.34) 9.39 (9.14–9.64)
Cardiac arrest 0.09 (0.06–0.11) 0.11 (0.08–0.14)
Hypertension 50.74 (50.31–51.16) 42.93 (42.51–43.35)
Myocardial infarction 4.18 (4.01–4.35) 4.67 (4.48–4.85)
Peripheral vascular disease 2.86 (2.72–3.01) 3.47 (3.31–3.63)
Thromboembolism 2.12 (2–2.25) 2 (1.87–2.12)
Gastrointestinal/hepatic
Cholecystitis 1.61 (1.5–1.72) 1.62 (1.51–1.73)
Gastric ulcers 0.74 (0.67–0.81) 0.94 (0.85–1.02)
Liver disease 0.49 (0.43–0.55) 0.39 (0.34–0.45)
Metabolic
Diabetes 14.29 (13.99–14.59) 12.8 (12.51–13.1)
Hyperglycemia 0.09 (0.07–0.12) 0.11 (0.08–0.14)
Musculoskeletal/rheumatic
Osteoarthritis 16.06 (15.74–16.37) 15.52 (15.2–15.83)
Rheumatalogic disease 2.08 (1.95–2.2) 2.38 (2.25–2.52)
Neurological/psychiatric
Alzheimer’s disease and
dementia
3.79 (3.63–3.95) 6.67 (6.46–6.87)
Depression 5.56 (5.36–5.76) 6.27 (6.06–6.48)
Hemiplegia 0.94 (0.86–1.02) 1.27 (1.18–1.37)
Pulmonary
Chronic obstructive
pulmonary disease
9.83 (9.57–10.08) 9.77 (9.51–10.03)
Renal
Nephrotic syndrome 0.06 (0.04–0.09) 0.08 (0.05–0.1)
Renal disease 1.33 (1.23–1.43) 1.49 (1.38–1.59)
Noncancer women are matched to women with breast cancer by time and
geographic area. All rates are standardized to the age and race/ethnicity
distribution of the cancer population.
CI, conﬁdence inteval.
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Figure 3. For women with breast cancer, the counts of both
physician encounters and new diagnostic tests during the
12-month precancer diagnosis period appeared to increase
beginning 3 months before the cancer diagnosis date. Statistical
models to estimate counts and rates in the precancer diagnosis
period were consistent with these ﬁgures after adjusting for age
and race/ethnicity, as well as accounting for censoring (i.e.
losses to follow-up and death). When we excluded the
3-month pre-diagnosis period from the statistical models
comparing utilization between women with and without breast
cancer, most of the difference in physician encounters and
virtually all of the difference in diagnostic testing were removed
(Table 4).
Analyses of the numbers of physician encounters and
unique diagnostic tests by stage showed that each measure was
inversely related to the stage of breast cancer at diagnosis. This
trend was consistent for both the entire 12-month period
Table 3. Estimates of 3-month and 12-month incidence of comorbid conditions in breast cancer and noncancer patients
Comorbid condition Breast cancer patients Noncancer patients Breast cancer patients Noncancer patients
3-month rate/1000 (95% CI) 3-month rate/1000 (95% CI) 12-month rate/1000 (95% CI) 12-month rate/1000 (95% CI)
Adverse events
Anemia 105.65 (99.79–111.52) 34.66 (31.33–37.99) 63.63 (61.29–65.97) 34.51 (32.8–36.21)
Diarrhea 15.61 (13.43–17.8) 7.09 (5.63–8.55) 11.01 (10.07–11.95) 6.88 (6.14–7.62)
Electrolyte disorder 124.04 (117.59–130.49) 49.17 (45.12–53.21) 78.69 (76.04–81.34) 47.13 (45.1–49.16)
Infectious disease 149.82 (142.62–157.02) 55.02 (50.64–59.39) 94.64 (91.68–97.6) 56.78 (54.51–59.06)
Infusion reaction 5.71 (4.4–7.02) 1.12 (0.53–1.71) 3.16 (2.66–3.66) 1.64 (1.28–2.01)
Neutropenia 17.48 (15.19–19.77) 0.3 (0–0.6) 15.6 (14.49–16.71) 0.8 (0.55–1.04)
Oral mucositis 2.02 (1.27–2.77) 0.07 (0–0.2) 2.15 (1.73–2.56) 0.12 (0.02–0.21)
Skin rash (medication related) 2.34 (1.5–3.18) 0.56 (0.14–0.98) 1.17 (0.86–1.47) 0.63 (0.41–0.86)
Skin rash (other) 35.34 (32.04–38.63) 10.07 (8.32–11.82) 20.85 (19.55–22.15) 10.43 (9.53–11.34)
Thrombocytopenia 11.52 (9.66–13.38) 3.26 (2.26–4.26) 8.23 (7.43–9.04) 3.72 (3.18–4.27)
Cardiac/vascular
Arrhythmia 52.25 (48.13–56.37) 15.69 (13.45–17.94) 25.56 (24.08–27.04) 16.28 (15.11–17.46)
Arterial thrombosis 2.73 (1.83–3.64) 1.3 (0.66–1.95) 1.97 (1.57–2.36) 1.41 (1.07–1.75)
Atrial ﬁbrillation 58.73 (54.32–63.15) 21.34 (18.72–23.96) 30.45 (28.82–32.08) 21.66 (20.31–23.02)
Coronary artery disease 80.31 (74.85–85.77) 28.77 (25.48–32.07) 35.35 (33.49–37.21) 26.61 (24.99–28.22)
Congestive heart failure 64.58 (59.91–69.25) 32.49 (29.17–35.8) 37.71 (35.88–39.54) 28.61 (27.02–30.19)
Cerebrovascular disease 42.16 (38.45–45.88) 23.88 (21.08–26.68) 24.55 (23.09–26) 22.24 (20.85–23.62)
Cardiac arrest 2.42 (1.57–3.27) 1.99 (1.22–2.77) 1.84 (1.46–2.22) 2.24 (1.82–2.65)
Hypertension 252.56 (239.88–265.24) 50.75 (45.5–55.99) 94.51 (90.49–98.53) 43.54 (41.05–46.02)
Myocardial infarction 45.12 (41.36–48.89) 15.24 (13.04–17.43) 21.7 (20.36–23.04) 16.53 (15.37–17.69)
Peripheral vascular disease 18.15 (15.79–20.52) 9.38 (7.66–11.1) 9.83 (8.94–10.72) 8.68 (7.84–9.51)
Thromboembolism 26.17 (23.34–29) 5.53 (4.24–6.83) 20.75 (19.46–22.05) 6.32 (5.61–7.02)
Gastrointestinal/hepatic
Cholecystitis 7.92 (6.37–9.47) 4.05 (2.9–5.2) 5.89 (5.2–6.57) 4.9 (4.26–5.53)
Gastric ulcers 4.63 (3.45–5.81) 2.93 (2.02–3.85) 3.29 (2.78–3.8) 3.42 (2.9–3.93)
Liver disease 3.13 (2.16–4.1) 1.04 (0.48–1.6) 1.7 (1.34–2.07) 1.25 (0.94–1.56)
Metabolic
Diabetes 34.96 (31.46–38.46) 13.48 (11.32–15.64) 17.17 (15.91–18.43) 11.32 (10.31–12.33)
Hyperglycemia 1.48 (0.81–2.15) 0.35 (0.04–0.66) 0.69 (0.46–0.93) 0.33 (0.17–0.49)
Musculoskeletal/rheumatic
Osteoarthritis 71.85 (66.76–76.93) 25.85 (22.83–28.87) 34.1 (32.29–35.9) 22.35 (20.91–23.79)
Rheumatalogic disease 8.99 (7.34–10.65) 2.73 (1.8–3.67) 3.97 (3.4–4.53) 2.66 (2.19–3.12)
Neurological/psychiatric
Alzheimer’s disease and dementia 37.9 (34.46–41.34) 19.02 (16.56–21.48) 20.78 (19.47–22.08) 21.3 (19.98–22.62)
Depression 44 (40.26–47.74) 14.27 (12.14–16.39) 23.55 (22.14–24.95) 14.59 (13.49–15.7)
Hemiplegia 7.79 (6.25–9.32) 4.53 (3.37–5.69) 4.74 (4.13–5.36) 4.41 (3.82–4.99)
Pulmonary
Chronic obstructive
pulmonary disease
78.02 (72.9–83.13) 19.08 (16.55–21.62) 33.06 (31.35–34.77) 18 (16.75–19.24)
Renal
Nephrotic syndrome 0.55 (0.14–0.95) 0.29 (0–0.58) 0.31 (0.15–0.46) 0.3 (0.15–0.44)
Renal disease 8.45 (6.85–10.05) 5.27 (4.01–6.53) 5.57 (4.91–6.24) 5.14 (4.51–5.77)
Noncancer patients are matched to cancer patients on gender, index date, and geographic area. All rates are standardized to the age and race/ethnicity
distribution of the cancer population. Rates are expressed per 1000 person-years.
CI, conﬁdence interval.
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pre-diagnosis period. In particular, patients presenting with
stage IV disease had 41% (95% CI 38% to 43%) fewer
physician encounters and 34% (95% CI 24% to 31%) fewer
unique diagnostic tests than women diagnosed with carcinoma
in situ when ignoring the 3-month pre-diagnosis period
(Table 4).
discussion
This study shows that older women, at the time of breast
cancer diagnosis, have a comparable prevalence of comorbid
conditions to women who do not have breast cancer. In
addition, stage at diagnosis is associated with variability in the
prevalence of many conditions, but the pattern of the
association is quite heterogeneous. In contrast, the incidence
rates of comorbid conditions, stratiﬁed by stage at diagnosis,
show that more advanced cancer stage is associated with a
greater likelihood of identifying new comorbid conditions.
Most importantly from a public health perspective, more
advanced stage at diagnosis is also associated with the degree
of precancer health system interaction, as measured by ofﬁce
visits and unique diagnostic tests. Hence, there is evidence for
a health care seeking behavioral component to the
undiagnosed comorbidity burden in breast cancer patients.
Looking more closely, older women with breast cancer
tended to have slightly lower prevalence rates for most
comorbid conditions compared with women without cancer,
even after accounting for age, race, time, and geographic
a r e a .S o m eo ft h i si sl i k e l yt ob er e l a t e dt oa nu n d e r -
diagnosis of conditions in women with later-stage disease, a
gap that shrinks after the cancer diagnosis. However, the
prevalence of several conditions was higher in women with
breast cancer than in those without, in contrast to the
overall pattern. For hypertension, diabetes, thromboembolic
events, and osteoarthritis, there is an established association
with higher body mass index (BMI), a confounder that
could not be controlled through standardization in these
data [22–28]. That is, because higher BMI is a risk factor
for breast cancer, our breast cancer population may have
been heavier, which may have increased the prevalence of
conditions associated with higher BMI [29, 30]. Similar
reasoning may apply to alcohol consumption and liver
disease [31, 32].
There are a variety of conﬂicting studies evaluating the
cross-sectional association between comorbidity burden and
breast cancer stage at diagnosis. Yancik et al. [4] found no
Figure 1. The prevalence of selected comorbid conditions in breast cancer patients by diagnosis stage. Comorbid conditions were selected to include a
variety of systems. See supplemental Appendix materials (available at Annals of Oncology online) for data on other conditions.
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Fleming et al. [33] found that the association between
comorbid conditions and advanced-stage diagnosis depended
on the comorbid condition. Vaeth et al. [34] found that
women with conditions causing functional limitations were
half as likely to be diagnosed with advanced-stage breast
cancer. Gonzalez et al. [35] found that a higher comorbidity
index was associated with higher odds of advanced-stage breast
cancer. In addition, similarly conﬂicting results exist for other
tumors as well [36, 37]. The presence of undiagnosed
conditions, many of which are found after cancer diagnosis,
appears to confound associations at the time of diagnosis.
In addition to our study, others have suggested that
interaction with the health system is a key factor in stage at
diagnosis. Gornick et al. [7] showed that the use of preventive
services was associated with a lower likelihood of late-stage
diagnosis for breast cancer, colorectal cancer, and prostate
cancer. Keating et al. [8] showed that women who saw a
medical provider in the 2 years before diagnosis were
signiﬁcantly less likely to be diagnosed with advanced-stage
disease. Furthermore, several studies have evaluated the use of
mammography and have shown that its use is associated with a
less-advanced stage at diagnosis [38, 39]. Our ﬁndings add
additional evidence to support the idea that cancer can be
identiﬁed early if women interact sufﬁciently, and
appropriately, with the system.
Our ﬁndings extend this previous work in several ways. First,
in the year before diagnosis (particularly when ignoring the 3-
month pre-diagnosis period), the overall patterns of medical
resource use for women with and without breast cancer were
remarkably similar. Based on this, there does not appear to be
any excess utilization in the year immediately preceding
diagnosis. Second, the increase in resource use that occurs
around diagnosis begins as early as 3 months before the month
of diagnosis. Hence, the time it takes to diagnose a woman
with breast cancer is variable, occurring over several months.
Third, the rate of newly diagnosed conditions is very high in
the 3-month period after the breast cancer diagnosis. These
ﬁndings have implications for researchers as well as clinicians,
particularly for researchers studying, or adjusting for, the effect
of comorbidity on outcomes.
Studies of the comorbid conditions identiﬁed after breast
cancer diagnosis are few. However, our results are comparable
to those from a recent study of comorbid conditions in 1183
breast cancer patients in the Health, Eating, Activity, and
Lifestyle Study (HEALS) [40]. In both HEALS and our study,
hypertension was the most common comorbid condition at the
time of diagnosis and also the most commonly identiﬁed new
Figure 2. The 3-month incidence of selected comorbid conditions in breast cancer patients by diagnosis stage. Comorbid conditions were selected to
include a variety of systems. See supplemental Appendix materials (available at Annals of Oncology online) for data on other conditions.
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higher rates of cardiovascular disease, which is not surprising
given that our SEER–Medicare population was notably older.
In addition, our study shows that many of these newly
identiﬁed conditions appear shortly after diagnosis (within 3
months), and in a period of time associated with a substantial
Figure 3. The unadjusted number of physician ofﬁce visits and unique diagnostic tests before and after the diagnosis index date. Counts in the above
ﬁgures do not show losses to follow-up after diagnosis. At 3 months the breast cancer and noncancer populations were 96% and 98% of the baseline total,
respectively (51590); at 6 months they were 94% and 96% of baseline, respectively; and at 12 months they were 90% and 93% of baseline, respectively.
Table 4. Outpatient visits and unique diagnostic tests in the year before the diagnosis index date for breast cancer and noncancer patients (both overall and
by stage)
Population Physician encounters Unique diagnostic tests
Mean Rate ratio (95% CI) Mean Rate ratio (95% CI)
Months −12 to −1 before diagnosis index date
Noncancer (overall) 4.99 1.00 (ref) 4.83 1.00 (ref)
Breast cancer (overall) 7.43 1.49 (1.47–1.51) 5.73 1.17 (1.16–1.19)
By stage In situ 8.26 1.00 (ref) 6.41 1.00 (ref)
I 7.86 0.95 (0.93–0.97) 6.01 0.94 (0.91–0.97)
II 7.14 0.86 (0.84–0.88) 5.39 0.84 (0.82–0.87)
III 5.52 0.66 (0.63–0.68) 4.15 0.65 (0.62–0.68)
IV 5.24 0.63 (0.60–0.65) 4.64 0.72 (0.69–0.76)
Unknown 6.68 0.79 (0.76–0.82) 5.63 0.89 (0.84–0.93)
Months −12 to −4 before diagnosis index date
Noncancer (overall) 4.87 1.00 (ref) 3.62 1.00 (ref)
Breast cancer (overall) 5.22 1.08 (1.06–1.09) 3.58 0.98 (0.96–1.00)
By stage In situ 5.77 1.00 (ref) 3.96 1.00 (ref)
I 5.54 0.95 (0.93–0.98) 3.76 0.95 (0.92–0.99)
II 5.04 0.86 (0.84–0.88) 3.41 0.86 (0.83–0.89)
III 3.92 0.66 (0.64–0.69) 2.70 0.68 (0.64–0.73)
IV 3.48 0.59 (0.57–0.62) 2.62 0.66 (0.62–0.71)
Unknown 4.72 0.80 (0.76–0.83) 3.57 0.91 (0.85–0.97)
Estimated by negative binomial regression and adjusted for age at diagnosis and race/ethnicity.
CI, conﬁdence interval.
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There are several key strengths to our analytic approach. The
use of a noncancer control group has not been used in other
related studies. Its inclusion is important because while claims
data are limited in their ability to identify all clinically relevant
disease, the control group facilitates internally consistent
comparisons. Also, the calculation of both incidence and
prevalence allows us to understand the complete picture of
comorbidity around the time of diagnosis. The large sample
size allows for more accurate rate estimation, particularly for
less common conditions. Finally, matching by time and
geographic area allows us to control for temporal trends and
geographic variation (as well as socioeconomic factors to a
limited degree), which can be difﬁcult to adjust for, while
allowing for analyses by race, stage, and age (not all of which
are shown).
However, the limitations of these analyses also deserve
discussion. The SEER–Medicare merged data lack certain
variables (e.g. BMI) that would be useful for comparing
women with and without breast cancer more precisely. In
addition, we did not have complete medical histories for
patients, particularly from their pre-Medicare coverage. Also,
we were limited to diagnoses that are included in claims data.
While studies have generally conﬁrmed that claims data are
reasonably sensitive and speciﬁc, there are limits to the
reliability of claims data for identifying comorbid conditions
[41, 42]. It is possible that some of the newly identiﬁed
conditions are the result of cancer-directed therapy initiated
shortly after diagnosis and are not previously undiagnosed
conditions. On the other hand, the strong and consistent
relationship across conditions between incidence and stage
suggests otherwise, particularly in conditions that should not
be related to breast cancer interventions (e.g. osteoarthritis).
Finally, our measures of physician encounters and unique
diagnostic testing are intentionally simplistic, and more
sophisticated measures focusing on speciﬁc diagnostic tools
and their utilization (as used by others) might provide
improved insights into the nature of the interactions between
providers and patients with respect to cancer diagnosis.
Even with these limitations, this study demonstrates that
older women with breast cancer suffer from a myriad of
comorbid conditions that may affect treatment and outcomes.
Many of these are identiﬁed as a consequence of the cancer
diagnosis. While some may result from common biological
pathways, there is also an important contribution from health-
seeking behavior before the cancer diagnosis. To the extent
that this behavior is modiﬁable, particularly with screening-
friendly reimbursement policies, it may be possible to ﬁnd
both cancer and comorbid conditions earlier and improve
survival.
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